Home>Corporate>Combining China’s Growth Momentum with Global Resource

Combining China’s Growth Momentum with Global Resource

Adhering to the concept of “Combining China’s Growth Momentum with Global Resource”, Fosun Pharma will continue to focus on innovation and internationalization, actively seek opportunities for industry M&A and integration on a global scale based on the established industry base, marketing network and M&A experience, and achieve comprehensive internationalization in R&D and development, marketing and operation, talents and capital through implementing strategies of “endogenous growth, extensive expansion, and integrated development”.

Revenue from overseas countries or regions amounted to RMB5,906.22 million, representing an increase of 76.26% as compared to 2017.
Fosun Pharma continued to strengthen marketing capabilities and has expanded the marketing team to nearly 5,300 people at home and abroad, with over 1,000 people in oversea marketing team.

Tridem Pharma is the third largest pharmaceutical distribution company in the French-speaking region of West Africa.
Fosun Pharma has established a mature sales network with profound upstream and downstream client resources in Francophone countries and regions in Africa.

Gland Pharma is a leading Indian pure-play generic injectable pharmaceutical products company. Fosun Pharma will leverage on Gland Pharma's own R&D capabilities and international drug registration capabilities, as well as Indian market's unique advantages on the generic drugs policy and cost advantage, in order to facilitate the industrial upgrade of the pharmaceutical manufacturing business and increase market share in global generic drugs market.

Fosun Pharma has actively promoted international standards. During the Reporting Period, Gland Pharma’s four pharmaceutical manufacturing facilities and three API manufacturing sites all passed audit or certifications in accordance with the drug regulations in the United States, Europe, Brazil and other countries. Furthermore, 1 oral solid formulation, 3 injectable formulations and 5 APIs of Guilin Pharma are prequalified by WHO; Yao Pharma’s oral solid formulation passed GMP inspection from Health Canada and FDA. In the future, the Group will continue to push forward the industrial upgrade of pharmaceutical manufacturing business, further expedite the internationalization process to improve the products market share in global market.